Back to Results
First PageMeta Content
Polycythemia vera / Essential thrombocytosis / Fibrosis / Medicine / Myeloproliferative disease / Myelofibrosis


Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre
Add to Reading List

Document Date: 2014-06-13 01:07:42

Open Document

File Size: 1,74 MB

Share Result on Facebook

City

Scottsdale / Houston / Macrophages Fibrocytes / Toronto / Milan / New York / /

Company

DIPSS Risk Group / 7Promedior Inc. / 3M / /

Country

United States / Italy / Canada / /

Currency

pence / /

Event

Product Issues / FDA Phase / Product Recall / /

Facility

Princess Margaret Cancer Centre / Cancer Institute / University of British Columbia / Paul’s Hospital / Sinai Medical Center / Cornell Medical Center / Anderson Cancer Center / /

MedicalCondition

abdominal pain / sialadenitis / pneumonia / disease / gastroenteritis / idiopathic pulmonary fibrosis / bone marrow fibrosis / reverse fibrosis / metabolic encephalopathy / cardiac arrest / renal failure / inflammation / Myelofibrosis / Inflammatory signals - Anti-fibrotic / fibrosis / /

Organization

Congress / 6Weil Cornell Medical Center / J. Gotlib8 1MD Anderson Cancer Center / Paul’s Hospital / 5Mount Sinai Medical Center / 4The Princess Margaret Cancer Centre / University of British Columbia / Vancouver / Stanford / /

Position

investigator / author / /

Product

Study / PTX-2 / PRM-151 / /

ProvinceOrState

Texas / British Columbia / New York / Arizona / Ontario / /

PublishedMedium

PLoS One / Baseline / /

Technology

pharmacokinetics / MRI / /

SocialTag